Detalles de la búsqueda
1.
Safety, tolerability, and effectiveness of repetitive intravenous dihydroergotamine for refractory chronic migraine with cardiovascular risk factors: A retrospective study.
Headache
; 63(9): 1251-1258, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37740562
2.
Long-term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis.
Headache
; 63(6): 730-742, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37313616
3.
Safety and tolerability of fremanezumab in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies.
Cephalalgia
; 42(8): 769-780, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35331009
4.
Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial.
Cephalalgia
; 42(1): 3-11, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34521260
5.
Guidelines of the International Headache Society for Clinic-Based Headache Registries, 1st edition.
Cephalalgia
; 42(11-12): 1099-1115, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35514209
6.
Efficacy and quality-of-life improvements with fremanezumab treatment in patients with difficult-to-treat migraine with associated neurological dysfunction.
Eur J Neurol
; 29(7): 2129-2137, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35302681
7.
Headache and rhinosinusitis: A review.
Cephalalgia
; 41(4): 453-463, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32954817
8.
Safety and efficacy of ubrogepant in participants with major cardiovascular risk factors in two single-attack phase 3 randomized trials: ACHIEVE I and II.
Cephalalgia
; 41(9): 979-990, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-33874756
9.
Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension.
Cephalalgia
; 41(1): 6-16, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33269951
10.
Guidelines of the International Headache Society for clinical trials with neuromodulation devices for the treatment of migraine.
Cephalalgia
; 41(11-12): 1135-1151, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33990161
11.
Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial.
Eur J Neurol
; 28(5): 1716-1725, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33400330
12.
A new hypothesis linking oxytocin to menstrual migraine.
Headache
; 61(7): 1051-1059, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34125955
13.
Intravenous ibuprofen for acute treatment of migraine: A double-blind, randomized, placebo-controlled pilot study.
Headache
; 61(9): 1432-1440, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34601736
14.
Chronic versus episodic migraine: The 15-day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency.
Headache
; 61(7): 992-1003, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34081791
15.
Evaluation of the 6-item Identify Chronic Migraine screener in a large medical group.
Headache
; 61(2): 335-342, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33421098
16.
The Use of Botulinum Toxin in the Management of Headache Disorders.
Handb Exp Pharmacol
; 263: 227-249, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-32562057
17.
Treatment benefit among migraine patients taking fremanezumab: results from a post hoc responder analysis of two placebo-controlled trials.
J Headache Pain
; 22(1): 2, 2021 Jan 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33413075
18.
Fremanezumab for the Preventive Treatment of Chronic Migraine.
N Engl J Med
; 377(22): 2113-2122, 2017 11 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-29171818
19.
Have the IHS Guidelines for controlled trials of acute treatment of migraine attacks been followed? Laying the ground for the 4th edition.
Cephalalgia
; 40(8): 778-787, 2020 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-32056459
20.
Comparison of healthcare resource utilization and costs among patients with migraine with potentially adequate and insufficient triptan response.
Cephalalgia
; 40(7): 639-649, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32223301